Latest News
& Press Releases
Browse the latest news from BioSpace, and press releases from around the industry. Want to filter by date, keyword, and more? Search here.
TOP STORIES
Seattle-based Sana Biotechnology went all-in on improving CAR T therapies against B cell cancers in two separate deals announced today.
The 2022 virtual J.P. Morgan Healthcare Conference got off to a roaring start Monday with deal announcements and plans to drive biopharma companies through the coming year.
The Centers for Disease Control recommends wearing a mask in health care settings and other places where people around may have risk factors for severe consequences of COVID-19.
Pfizer has reported that an Omicron-specific vaccine will be available in March, should it be necessary. For those and more COVID-19 news, continue reading.
Sarepta Therapeutics shared positive topline results from its ongoing SRP-9001-102 study on the effectiveness of delandistrogene moxeparvovec in treating Duchenne muscular dystrophy.
BioSpace picked the brains of 10 biotech CEOs and founders, to solicit their advice for first-time founders.
The company has produced a varied pipeline focused on the development of precision pharmacological treatments for nine different programs.
Another drug Vounatsos heralded was zuranolone, which Biogen is developing with Sage Therapeutics for multiple forms of depression.
Allogene announced that the chromosomal abnormality was not detected in any manufactured AlloCAR T product or any patient treated with the same lot of drugs.
Moderna roared through 2021 on the strength of its COVID-19 vaccine and that momentum is continuing in 2022.
Sigyn is not only trying to treat the inflammatory mediators that fuel sepsis; it wants to prevent the life-threatening event from occurring altogether.
BMS and Century Therapeutics agreed to collaborate on the research, development, and commercialization of up to four T cell programs for hematologic malignancies and solid tumors.